New company to take over handling of European business for berotralstat

An Italian pharmaceutical company, called Neopharmed Gentili, have signed a deal with BioCryst to take over the entire European berotralstat (Orladeyo) business.

BioCryst has confirmed that Neopharmed Gentili is acquiring its entire European organization, which will enable commercial continuity for people with HAE who use berotralstat to treat their condition.

Jon Stonehouse, President and Chief Executive Officer of BioCryst, said: “This transaction is consistent with our strategy of making Orladeyo available to patients in Europe through the team we built.”

Alessandro Del Bono, President and Chief Executive Officer of Neopharmed Gentili, said: “This transaction marks the beginning of a new path for Neopharmed Gentili, projecting the company onto the international stage and rare disease field, leveraging its deep Italian roots and welcoming a successful and experienced European team.”

(Source: BioCryst)